Loading...
Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites
BACKGROUND: Non-Hodgkin lymphoma (nhl) is the most common hematologic malignancy. Diffuse large B-cell lymphoma (dlbcl) and follicular lymphoma (fl) constitute 55% of new nhl cases and are initially treated with rituximab-based chemoimmunotherapy. Relative to intravenous (IV) rituximab, a subcutaneo...
Na minha lista:
| Udgivet i: | Curr Oncol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Multimed Inc.
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6209563/ https://ncbi.nlm.nih.gov/pubmed/30464679 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.4231 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|